Stabilization of retinoid compounds

ABSTRACT

The present invention relates to a method of administering a compound of Formula I:  
                 
wherein 
         R 1  is hydrogen or C 1-6 -alkyl;    R 2  is C 1-6 -alkyl or adamantyl;    R 3  is C 1-6 -alkyl or hydroxy; or    R 2  and R 3  taken together are —(CR 6 R 7 ) n —;    R 4  is C 2-8 -alkyl, C 2-8 -alkenyl, C 2-8 -alkynyl, —OCH 2 R 5  or C 2-8 -alkanoyl, or hydrogen when R 3  is hydroxy;    R 5  is C 1-6 -alkyl, C 2-6 -alkenyl or C 2-6 -alkynyl;    R 6  and R 7  are hydrogen or C 1-6 -alkyl; Y is oxygen or sulfur; and n is 3, 4, or 5, or a pharmaceutically acceptable salts of carboxylic acid of formula I, wherein said method comprises the step of admixing said compound in solid form with a topical carrier to form a topical formulation within seven days prior to first topical administration of said compound.

CROSS-REFERENCE

This application claims priority from provisional application Ser. No.60/262,687 filed on Jan. 19, 2001.

FIELD OF THE INVENTION

The present invention relates to the topical delivery of retinoidcompounds.

BACKGROUND OF THE INVENTION

Retinoic acid is a retinoid sold both for the topical treatment of acne(Retin-A®, Ortho Dermatological, Skillman, N.J.) and for the topicaltreatment of fine wrinkles, mottled hyperpigmentation, and tactileroughness of facial skin (Renova®, Ortho Dermatological). The compoundis formulated into a variety of topical gels, creams, and solutions.

U.S. Pat. No. 5,726,191 recently reported a new class of retinoids.According to the '191 Patent, these compounds can be topicallyadministered in ointments, tinctures, creams, solutions, lotions,sprays, and suspensions. Applicants, however, have found that whilemembers of this class of compounds were very potent in binding to theretinoid receptor, they are chemically unstable in topical formulations.

In fact, applicants tested Compound I, a compound from this class, in avast array of topical liquid or semisolid pharmaceutical formulations.None of these formulations, however, were capable of sufficientlystabilizing the compound when stored at room temperature (between 20 to30° C.), thus, inhibiting the ability to market the compound in atopical formulation.

The present invention relates to stabilizing this new class of retinoidsin a manner suitable for topical administration.

SUMMARY OF THE INVENTION

In one aspect, the invention features a method of administering acompound of Formula I (defined herein), wherein the method includes thestep of admixing the compound in solid form with a topical carrier toform a topical formulation within seven days prior to first topicaladministration of the compound.

In another aspect, the invention features a kit comprising two chambers,wherein the first chamber contains a compound in solid form and thesecond chamber contains a topical carrier in an amount capable ofdissolving or dispersing said compound where the compound is of FormulaI.

Other features and advantages of the present invention will be apparentfrom the detailed description of the invention and from the claims.

DETAILED DESCRIPTION OF THE INVENTION

It is believed that one skilled in the art can, based upon thedescription herein, utilize the present invention to its fullest extent.The following specific embodiments are to be construed as merelyillustrative, and not limitative of the remainder of the disclosure inany way whatsoever.

Unless defined otherwise, all technical and scientific terms used hereinhave the same meaning as commonly understood by one of ordinary skill inthe art to which the invention belongs. Also, all publications, patentapplications, patents, and other references mentioned herein areincorporated by reference.

In one aspect, the present invention relates to a method ofadministering a compound of Formula I

wherein

-   -   R¹ is hydrogen or C₁₋₆-alkyl;    -   R² is C₁₋₆-alkyl or adamantyl;    -   R³ is C₁₋₆-alkyl or hydroxy; or    -   R² and R³ taken together are —(CR⁶R⁷)_(n)—;    -   R⁴ is C₂₋₈-alkyl, C₂₋₈-alkenyl, C₂₋₈-alkynyl, —OCH₂R⁵ or        C₂₋₈-alkanoy, or hydrogen when R³ is hydroxy;    -   R⁵ is C₁₋₆-alkyl, C₂₋₆-alkenyl or C₂₋₆-alkynyl;    -   R⁶ and R⁷ are hydrogen or C₁₋₆-alkyl;    -   Y is oxygen or sulfur; and    -   n is 3, 4, or 5,        or a pharmaceutically acceptable salts of the carboxylic acid of        formula I.

The notations “C₁₋₆”, “C₂₋₆”, and “C₂₋₈” used herein stand for groupswith from 1 to 6, from 2 to 6 and from 2 to 8 carbon atoms,respectively. Alkyl residues can be straight-chain or branched. Thealkyl residues of R¹ may be straight-chain such as methyl, ethyl,propyl, butyl, pentyl and hexyl. Alkyl residues of R² and R³ may bebranched alkyl residues such as tert-butyl. Alkyl residues of R⁴ and R⁵may be straight-chain such as ethyl, propyl, butyl, pentyl, and hexyl.Examples of alkenyl residues are straight-chain alkenyl residues such asvinyl, 1- and 2- propenyl, and 2-butenyl. Ethynyl, 1- and 2-propynyl and1- and 2-butynyl are examples of alkynyl residues. Examples ofC₂₋₈-alkanoyl residues are straight-chain alkanoyl residues such asacetyl, propionyl, butyryl, pentanoyl, hexanoyl, heptanoyl and octanoyl.

In one embodiment of the invention the pyridine-carboxylic acid residuein the compounds of Formula I is a nicotinic acid residue, that is, whenR¹ is hydrogen (e.g., a nicotinic acid residue linked in the 5- or6-position). In one embodiment, R² and R³ taken together are—(CR⁶R⁷)_(n)—. In a further embodiment, R² and R³ taken together are—C(CH₃)₂CH₂CH₂C(CH₃)₂—, —C(CH₃)₂(CH₃)₂—, or —C(CH₃)₂(CH₂)₄—. In oneembodiment, Y is oxygen. In one embodiment, R⁴ is C₂₋₈-alkyl. In oneembodiment, R¹ is hydrogen.

Examples of compounds of Formula I are the-following:

Other examples of compounds of formula I are:

-   -   6-(3-hexyl-5,5-dimethyl-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-        yl-carbonyloxy)-nicotinic acid,    -   6-(3-hex-1-enyl-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl-carbonyloxy)-nicotinic        acid,    -   6-(6-hexyl-3,3-dimethyl-indan-5-yl-carbonyloxy)-nicotinic acid,    -   6-(3-butoxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl-carbonyloxy)-nicotinic        acid,    -   6-(3-adamantan-1-yl-4-hydroxy-benzoyloxy)-nicotinic acid,    -   6-(3-hexanoyl-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl-carbonyloxy)-nicotinic        acid, and    -   6-(3-hexyl-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl-carbonylsulphanyl)-nicotinic        acid.

Methods of manufacturing compounds of the present invention are setforth in U.S. Pat. No. 5,726,191.

In one embodiment, the topical carrier substantially dissolves saidcompound (e.g., dissolves at least 90% of the compound). In oneembodiment, the topical carrier suspends the compound. In oneembodiment, the composition comprises about 0.001% to about 1%, byweight, of the compound (e.g., about 0.01% to about 0.1%, by weight).

In one embodiment, the method includes admixing a unit dose of thecompound (e.g., an amount of the compound sufficient for a singleapplication of the compound). In a further embodiment, the topicalcarrier comprises an alcohol. Examples of such alcohols include, but arenot limited to, the group consisting of ethanol, isopropyl alcohol, andpropylene glycol. In one embodiment, the topical carrier furtherincludes an gelling agent. In one-embodiment, the gelling agent is anoil-soluble gelling agent. Suitable gelling agents for oils (such asmineral oil) include, but are not limited to, hydrogenatedbutylene/ethylene/styrene copolymer and hydrogenatedethylene/propylene/styrene copolymer. Such gels typically comprisesbetween about 0.1% and 5%, by weight, of such gelling agents.

In another embodiment, the method includes admixing multiple unitdosages of the compound. In a further embodiment, the topical carriercomprises a member selected from the group consisting of diisopropyladipate, diisopropyl sebacate, diisocetyl adipate, triacetin,caprylic/capric triglyceride, and isopropyl myristate. In a furtherembodiment, the method further includes the step of refrigerating theresulting formulation during the course of administration of themultiple unit dosages.

In one embodiment, the method further comprises admixing the formulationcontaining the compound with a cream (e.g., a water-in-oil emulsion oroil-in-water emulsion) or a gel (e.g., an aqueous, petrolatum, orsilicone gel).

In another aspect, the invention features a kit comprising two chambers,wherein the first chamber contains the compound in solid form and thesecond chamber contains a topical carrier in an amount capable ofdissolving or dispersing said compound where the compound is of FormulaI.

In one embodiment, the topical carrier is in an amount capable ofsubstantially dissolving the compound. In one embodiment, the topicalcarrier is in an amount capable of suspending the compound.

In one embodiment, the first chamber contains a unit dose of thecompound. In a further embodiment, the topical carrier contains analcohol. In a further embodiment, the second chamber further contains agelling agent.

In one embodiment, the first chamber contains multiple unit dosages ofthe compound. In a further embodiment, the solvent is selected from thegroup consisting of diisopropyl adipate, diisopropyl sebacate,diisocetyl adipate, triacetin, caprylic/capric triglyceride, andisopropyl myristate. In a further embodiment, the kit further includes alabel instructing the user to refrigerate the compound followingdissolution.

In one embodiment, the kit further comprises a third chamber containinga cream (e.g., a water-in-oil emulsion or oil-in-water emulsion) or agel (e.g., an aqueous, petrolatum, or silicone gel).

In one embodiment, the first chamber and second chamber are separatecontainers (e.g., vials). The contents of one container may then beadded and admixed with the contents of the other container (e.g., thecompound may be removed from its container and added and admixed withthe topical carrier in its container). In a further embodiment, theresulting mixture is administered by using a wipe applicator that may ormay not be stored within the other container. Examples of suchadministration is well known in the art, e.g., Benzamycin® topical gel.

In another embodiment, the two chambers are within the same container,but are separated by a wall that is breakable upon the application offorce. Examples of two chamber packages for delivery of unit dosages arewell known in the art and are available from supplier such as KlockeVerpackungs GmbH (Weingarten, Germany). In a further embodiment, theresulting mixture is administered by using a wipe applicator that may ormay not be stored within the container.

Unit dosages may also be administered using applicator stick wherein thetopical carrier is stored within the shaft of the applicator andseparated from the applicator end of stick by a breakable wall. Thecompound of Formula 1 is contained within the applicator end of thestick (e.g., a foam or fabric tip). Upon rupturing the breakable wall,the topical carrier enters the foam head and dissolves/suspends thecompound. Examples of such applicators are well known in the art, e.g.,Betadine PrepStick™ applicator (Purdue Frederick, Norwalk, Conn.).

The compounds of the present invention are useful in the treatment orprevention of skin disorders such as acne, psoriasis, photo-damage,environmental damage, intrinsic age damage, wrinkles, tumors (e.g.,melanomas), hyperpigmentation, and skin roughness. The compounds of thepresent invention may also be used for the promotion of wound healing.Other uses of the present invention are set forth in U.S. Pat. No.5,726,191.

As discussed above, compounds of the present invention were found to bechemically unstable once formulated into a topical carrier. What ismeant by a topical carrier is a liquid or semi-solid formulation capableof being applied topically to the skin. Examples of topical carriersinclude, but are not limited to, ointments, sprays, creams, lotions (e.g., solutions, suspensions and emulsions), or gels. The topical carrieris preferably anhydrous.

Thus, in order to ensure stability of such compounds, they must bestored in solid form, and then reformulated into a topical carrierproximate to the time of first application (e.g., within seven daysprior to the first topical administration of said compound). In oneembodiment, the compound is reformulated within forty-eight (48) hoursprior to first topical administration of said compound. In oneembodiment, the compound is mixed by a doctor, pharmacist, or by the enduser.

The following is a description of the manufacture of various topicalformulations of the present invention. Other formulations of theinvention can be prepared in an analogous manner by a person of ordinaryskill in the art.

EXAMPLE 1

The stability of Compound I was tested in the following twenty-eightdifferent topical formulations, set forth in Table 1. Finsolv® TN is aC12-15 alkyl benzoate from Fintex, Inc. (Elmwood Park, N.J.) Miglyol®812 from Huls AG (Marl, Germany) and Neobee® 1053 from Stepan Company(Northfield, Ill.) are each a caprylic/capric triglyceride. TABLE 1Formulation No. Carrier Volume % Formulation 1 Diisopropyl sebacate 100Formulation 2 Diisopropyl sebacate 60 Cyclomethicone 40 Formulation 3Miglyol ® 812 100 Formulation 4 Isopropyl laurate 100 Formulation 5Diisopropyl sebacate 50 Isopropyl laurate 50 Formulation 6 Diisopropyladipate 50 Cyclomethicone 50 Formulation 7 Diisopropyl adipate 100Formulation 8 Diisopropyl adipate 50 Isopropyl laurate 50 Formulation 9Propylene glycol 100 Formulation 10 PEG 400 100 Formulation 11 Propylenecarbonate 100 Formulation 12 Dimethyl isosorbide 100 Formulation 13Miglyol ® 812 100 Formulation 14 Finsolv ® TN 100 Formulation 15Glycerin 100 Formulation 16 Isopropyl myristate 100 Formulation 17Cyclomethicone 100 Formulation 18 Dimethicone 100 Formulation 19 Mineraloil 100 Formulation 20 Sunflower oil 100 Formulation 21 Soybean oil 100Formulation 22 Neobee ® 1053 100 Formulation 23 Sesame oil 100Formulation 24 Butyl Acetate 100 Formulation 25 Isopropanol 100Formulation 26 PEG 400 30 Ethanol 70 Formulation 27 Triacetin 100Formulation 28 Tributyrin 100

The general procedure to prepare the above formulations is as follows. A500 mg of Compound 1 was weighed and transferred into an 800 ml glassbeaker containing 500 g of one of the above carriers. The formulationwas then stirred with a paddle mixer (stirrer type RZR50 from Caframo inWiarton, Ontario, Canada) at 100 RPM setting until the compound wascompletely dissolved/dispersed in the carrier.

About 20 g each of the resulting formulations were then packed into 24clear glass scintillation vials of 20 ml volume (Wheaton DisposableScintillation Vials from Wheaton Scientific in Milleville, N.J.) andlabeled. Groups of eight of such vials were then stored at 4° C., RT(22° C.) and/or 40° C. for stability studies.

The samples of the formulations at each of the above three temperatureswere then periodically analyzed for the chemical stability ofCompound 1. The compound was assayed using high performance liquidchromatographic (HPLC) system. The results of this analysis is set forthin Table 2 setting forth the amount of Compound 1 remaining in theformulation following a certain number of days at specifiedtemperatures. Chemical degradation of Compound 1 was seen in all of theformulations stored at 22° C. and/or 40° C., thus, demonstrating a needto make the formulation proximate to the time of administration and/orrefrigerate the formulation after it is made. TABLE 2 % RemainingFormulation No. Days 4° C. 22° C. 40° C. Formulation 1 84 102 89 64Formulation 2 84 101 90 68 Formulation 3 56 100 93 60 Formulation 4 56100 97 87 Formulation 5 56 100 96 80 Formulation 6 90 87 84 63Formulation 7 90 87 80 57 Formulation 8 90 100 93 69 Formulation 9 3682.39 — 0.71 Formulation 10 36 93.56 — 0.71 Formulation 11 70 100.77 —40.18 Formulation 12 18 96.84 — 65.36 Formulation 13 70 93.46 — 49.09Formulation 14 36 100.48 — 2.23 Formulation 15 29 97.44 — 84.09Formulation 16 22 95.43 — 86.18 Formulation 17 85 100 — 83 Formulation18 30 98.16 — 76.18 Formulation 19 70 104.83 — 84.83 Formulation 20 70102.20 — 51.83 Formulation 21 22 101.34 — 83.82 Formulation 22 21 10097.38 88.62 Formulation 23 23 102.66 — 86.77 Formulation 24 34 100 —55.48 Formulation 25 18 100 80.79 5.96 Formulation 26 13 100 86.74 9.13Formulation 27 23 100 96.41 93.81 Formulation 28 22 100 97.49 86.08

It is understood that while the invention has been described inconjunction with the detailed description thereof, that the foregoingdescription is intended to illustrate and not limit the scope of theinvention, which is defined by the scope of the appended claims. Otheraspects, advantages, and modifications are within the claims.

1 (canceled) 2 (canceled) 3 (canceled) 4 (canceled) 5 (canceled) 6 (canceled) 7 (canceled) 8 (canceled) 9 (canceled) 10 (canceled) 11 A kit comprising two chambers, wherein said first chamber comprises a compound in solid form and the second chamber comprises a topical carrier in an amount capable of dissolving or dispersing said compound where said compound is of Formula I

wherein R¹ is hydrogen or C₁₋₆-alkyl; R² is C₁₋₆-alkyl or adamantyl; R³ is C₁₋₆-alkyl or hydroxy; or R² and R³ taken together are —CR⁶R⁷)_(n)—; R⁴ is C₂₋₈-alkyl, C₂₋₈-alkenyl, C₂₋₈-alkynyl, —OCH₂R⁵ or C₂₋₈-alkanoyl, or hydrogen when R³ is hydroxy; R⁵ is C₁₋₆-alkyl, C₂₋₆-alkenyl or C₂₋₆-alkynyl; R⁶ and R⁷ are hydrogen or C₁₋₆-alkyl; Y is oxygen or sulfur; and n is 3, 4, or 5, or a pharmaceutically acceptable salts of carboxylic acid of formula I. 12 A kit of claim 11, wherein said topical carrier is in an amount capable of substantially dissolving said compound. 13 A kit of claim 11, wherein said topical carrier is in an amount capable of suspending said compound. 14 A kit of claim 12, wherein said second chamber comprises a unit dose of said compound and said topical carrier comprises an alcohol. 15 A kit of claim 14, wherein said alcohol is selected from the group consisting of ethanol, isopropyl alcohol or propylene glycol. 16 A kit of claim 11, wherein said first chamber further comprises a gelling agent. 17 A kit of claim 12, wherein said first chamber comprises multiple unit dosages of said compound and said solvent is selected from the group consisting of diisopropyl adipate, diisopropyl sebacate, diisocetyl adipate, triacetin, caprylic/capric triglyceride, and isopropyl myristate. 18 A kit of claim 17, wherein said kit further comprises a label instructing the user to refrigerate said formulation. 19 A kit of claim 11, wherein said compound is in an amount of about 0.01% to about 0.1%, by weight, of the combined weight of the compound and the topical carrier. 20 A kit of claim 12, wherein said kit further comprises a third chamber comprising a cream or a gel. 